93 related articles for article (PubMed ID: 16940715)
1. Impact of angiotensin II receptor blocker on plasma levels of adiponectin and advanced oxidation protein products in peritoneal dialysis patients.
Furuya R; Odamaki M; Kumagai H; Hishida A
Blood Purif; 2006; 24(5-6):445-50. PubMed ID: 16940715
[TBL] [Abstract][Full Text] [Related]
2. Effects of angiotensin II type 1 receptor blocker on blood pressure variability and cardiovascular remodeling in hypertensive patients on chronic peritoneal dialysis.
Shigenaga A; Tamura K; Dejima T; Ozawa M; Wakui H; Masuda S; Azuma K; Tsurumi-Ikeya Y; Mitsuhashi H; Okano Y; Kokuho T; Sugano T; Ishigami T; Toya Y; Uchino K; Tokita Y; Umemura S
Nephron Clin Pract; 2009; 112(1):c31-40. PubMed ID: 19342867
[TBL] [Abstract][Full Text] [Related]
3. Relationship of pregnancy-associated plasma protein-a to renal function and dialysis modalities.
Fialová L; Kalousová M; Soukupová J; Sulková S; Merta M; Jelínková E; Horejsí M; Srámek P; Malbohan I; Mikulíková L; Tesar V; Zima T
Kidney Blood Press Res; 2004; 27(2):88-95. PubMed ID: 14739577
[TBL] [Abstract][Full Text] [Related]
4. Telmisartan but not candesartan affects adiponectin expression in vivo and in vitro.
Yamada S; Ano N; Toda K; Kitaoka A; Shiono K; Inoue G; Atsuda K; Irie J
Hypertens Res; 2008 Apr; 31(4):601-6. PubMed ID: 18633170
[TBL] [Abstract][Full Text] [Related]
5. Anti-inflammatory and metabolic effects of candesartan in hypertensive patients.
Koh KK; Quon MJ; Han SH; Chung WJ; Lee Y; Shin EK
Int J Cardiol; 2006 Mar; 108(1):96-100. PubMed ID: 16246439
[TBL] [Abstract][Full Text] [Related]
6. The effect of angiotensin II receptor blocker on peritoneal membrane transports in continuous ambulatory peritoneal dialysis patients.
Jearnsujitwimol V; Eiam-Ong S; Kanjanabuch T; Wathanavaha A; Pansin P
J Med Assoc Thai; 2006 Aug; 89 Suppl 2():S188-95. PubMed ID: 17044472
[TBL] [Abstract][Full Text] [Related]
7. Role of RAAS and adipokines in cardiovascular protection: effect of different doses of angiotensin II receptor blocker on adipokines level in hypertensive patients.
Hass A; Oz H; Mashavi M; Shargorodsky M
J Am Soc Hypertens; 2014 Oct; 8(10):709-14. PubMed ID: 25418492
[TBL] [Abstract][Full Text] [Related]
8. AT1 receptor antagonist candesartan attenuates genomic damage in peripheral blood lymphocytes of patients on maintenance hemodialysis treatment.
Schupp N; Rutkowski P; Sebeková K; Klassen A; Bahner U; Grupp C; Heidland A; Stopper H
Kidney Blood Press Res; 2011; 34(3):167-72. PubMed ID: 21474964
[TBL] [Abstract][Full Text] [Related]
9. Effect of low-dose dual blockade of renin-angiotensin system on urinary TGF-beta in type 2 diabetic patients with advanced kidney disease.
Song JH; Cha SH; Lee HJ; Lee SW; Park GH; Lee SW; Kim MJ
Nephrol Dial Transplant; 2006 Mar; 21(3):683-9. PubMed ID: 16330466
[TBL] [Abstract][Full Text] [Related]
10. Effects of combined candesartan and ACE inhibitors on BNP, markers of inflammation and oxidative stress, and glucose regulation in patients with symptomatic heart failure.
White M; Lepage S; Lavoie J; De Denus S; Leblanc MH; Gossard D; Whittom L; Racine N; Ducharme A; Dabouz F; Rouleau JL; Touyz R
J Card Fail; 2007 Mar; 13(2):86-94. PubMed ID: 17395047
[TBL] [Abstract][Full Text] [Related]
11. Beneficial effects of icodextrin on plasma level of adipocytokines in peritoneal dialysis patients.
Furuya R; Odamaki M; Kumagai H; Hishida A
Nephrol Dial Transplant; 2006 Feb; 21(2):494-8. PubMed ID: 16221697
[TBL] [Abstract][Full Text] [Related]
12. Safety and tolerability of high-dose angiotensin receptor blocker therapy in patients with chronic kidney disease: a pilot study.
Weinberg AJ; Zappe DH; Ashton M; Weinberg MS
Am J Nephrol; 2004; 24(3):340-5. PubMed ID: 15192304
[TBL] [Abstract][Full Text] [Related]
13. Combined vascular effects of HMG-CoA reductase inhibitor and angiotensin receptor blocker in non-diabetic patients undergoing peritoneal dialysis.
Han SH; Kang EW; Yoon SJ; Yoon HS; Lee HC; Yoo TH; Choi KH; Han DS; Kang SW
Nephrol Dial Transplant; 2011 Nov; 26(11):3722-8. PubMed ID: 21385862
[TBL] [Abstract][Full Text] [Related]
14. Chronic administration of an angiotensin II receptor antagonist resets the hypothalamic-pituitary-adrenal (HPA) axis and improves the affect of patients with diabetes mellitus type 2: preliminary results.
Pavlatou MG; Mastorakos G; Lekakis I; Liatis S; Vamvakou G; Zoumakis E; Papassotiriou I; Rabavilas AD; Katsilambros N; Chrousos GP
Stress; 2008 Jan; 11(1):62-72. PubMed ID: 17853061
[TBL] [Abstract][Full Text] [Related]
15. Combination therapy of angiotensin II receptor blocker and calcium channel blocker exerts pleiotropic therapeutic effects in addition to blood pressure lowering: amlodipine and candesartan trial in Yokohama (ACTY).
Maeda A; Tamura K; Kanaoka T; Ohsawa M; Haku S; Azushima K; Dejima T; Wakui H; Yanagi M; Okano Y; Fujikawa T; Toya Y; Mizushima S; Tochikubo O; Umemura S
Clin Exp Hypertens; 2012; 34(4):249-57. PubMed ID: 22571446
[TBL] [Abstract][Full Text] [Related]
16. Total and high molecular weight adiponectin concentrations in plasma of patients with end-stage renal disease before and after peritoneal dialysis.
Park JH; Gil HW; Yang JO; Lee EY; Hong SY
Nephrology (Carlton); 2008 Jun; 13(3):181-5. PubMed ID: 18315699
[TBL] [Abstract][Full Text] [Related]
17. Differential effects of candesartan and olmesartan on adipose tissue activity biomarkers in type II diabetic hypertensive patients.
Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Gravina A; Mereu R; Palumbo I; Fogari E; D'Angelo A; Cicero AF
Hypertens Res; 2010 Aug; 33(8):790-5. PubMed ID: 20505674
[TBL] [Abstract][Full Text] [Related]
18. An angiotensin receptor blocker reduces the risk of congestive heart failure in elderly hypertensive patients with renal insufficiency.
Nakamura T; Kanno Y; Takenaka T; Suzuki H;
Hypertens Res; 2005 May; 28(5):415-23. PubMed ID: 16156505
[TBL] [Abstract][Full Text] [Related]
19. Effects of an ARB on endothelial progenitor cell function and cardiovascular oxidation in hypertension.
Yu Y; Fukuda N; Yao EH; Matsumoto T; Kobayashi N; Suzuki R; Tahira Y; Ueno T; Matsumoto K
Am J Hypertens; 2008 Jan; 21(1):72-7. PubMed ID: 18091747
[TBL] [Abstract][Full Text] [Related]
20. Effects of an ACE inhibitor or angiotensin receptor blocker on potassium in CAPD patients.
Phakdeekitcharoen B; Leelasa-nguan P
Am J Kidney Dis; 2004 Oct; 44(4):738-46. PubMed ID: 15384026
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
